ReviewIndian journal of ophthalmology2026
New pharmacological and biotechnological approaches for the treatment of neurotrophic keratopathy: From growth factors to gene therapy.
Review in Indian journal of ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Neurotrophic keratopathy (NK) is a serious ocular surface disease that develops due to a reduction or loss of corneal innervation. Conventional therapeutic approaches, such as the use of artificial tears and autologous serum, primarily serve as symptomatic relief measures and do not target the underlying neurodegenerative process. The introduction of recombinant human nerve growth factor (rhNGF, cenegermin) has marked the first disease-modifying pharmacological therapy for NK, providing evidence of enhanced epithelial healing and improved corneal sensitivity. In recent years, with biotechnological advancements and the emergence of genetic therapy strategies, the importance of pathophysiology-oriented treatments in NK therapy has increased. The objective of this review is to offer an analysis of the management of NK in the context of recent pharmacological and biotechnological advancements in the light of current literature. This review aims to provide an integrated and pathophysiology-oriented synthesis of NK management, uniquely bridging pharmacological treatments with emerging biotechnological strategies including gene therapy, cell-based approaches, and novel drug delivery systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.